Pomerantz Law Firm Investigates Claims Against Celcuity Inc. Investors

Pomerantz LLP announced on July 16, 2026, that it is investigating claims on behalf of investors of Celcuity Inc. (NASDAQ: CELC). The investigation will determine if Celcuity or its officers and directors have engaged in securities fraud or other unlawful business practices.

The investigation follows Celcuity's press release on July 14, 2026, which announced U.S. Food and Drug Administration approval for its breast cancer therapy Revtorpyk (gedatolisib). The company indicated an anticipated commercial launch in late Q3 2026, a timeline that appeared to be a delay compared to analyst expectations.

Following the announcement, Celcuity's stock price declined significantly. Analysts from Stifel, Stephen Wiley, and Leerink, Andrew Berens, commented that the late Q3 launch guidance seemed extended relative to prior expectations and company commentary.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is recognized for its work in corporate and securities litigation. The firm has a history of recovering substantial damages for victims of securities fraud.